Page last updated: 2024-09-03

mk 0663 and Thromboembolism

mk 0663 has been researched along with Thromboembolism in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Aldington, S; Beasley, R; Shirtcliffe, P; Weatherall, M	1
Broich, K; Heim, HK	1

Reviews

1 review(s) available for mk 0663 and Thromboembolism

Article	Year
Systematic review and meta-analysis of the risk of major cardiovascular events with etoricoxib therapy. The New Zealand medical journal, 2005, Oct-07, Volume: 118, Issue:1223 Topics: Cyclooxygenase Inhibitors; Double-Blind Method; Etoricoxib; Humans; Musculoskeletal Diseases; Pyridines; Randomized Controlled Trials as Topic; Risk; Sulfones; Thromboembolism	2005

Other Studies

1 other study(ies) available for mk 0663 and Thromboembolism

Article	Year
Selective COX-2 inhibitors and risk of thromboembolic events - regulatory aspects. Thrombosis and haemostasis, 2006, Volume: 96, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Animals; Arthritis; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Approval; Drug Evaluation, Preclinical; Etoricoxib; European Union; Humans; Lactones; Product Surveillance, Postmarketing; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Risk Assessment; Sulfonamides; Sulfones; Thromboembolism	2006

Article

Year

Selective COX-2 inhibitors and risk of thromboembolic events - regulatory aspects.

Thrombosis and haemostasis, 2006, Volume: 96, Issue:4

Topics: Adverse Drug Reaction Reporting Systems; Animals; Arthritis; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Approval; Drug Evaluation, Preclinical; Etoricoxib; European Union; Humans; Lactones; Product Surveillance, Postmarketing; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Risk Assessment; Sulfonamides; Sulfones; Thromboembolism

2006